Category: Uncategorized

THE US GENERICS INDUSTRY HAS SAVED CONSUMERS ONE TRILLION USD IN TEN YEARS (Generic Pharmaceutical Association study with IMS Health 2012). Similar savings are predicted for generic biologicals. In 1984 the Hatch-Waxman Act opened the doors for the modern generics industry by creating incentives for generic drug makers. At that time it was estimated that 10 year savings might be one billion, but by 1994 it was ~10 billion USD. Since then, those savings have grown exponentially. Many of the early innovators of the industry are now dead, but they have left a phenomenal legacy. View in LinkedIn

SOME READERS ARE SURPRISED ABOUT DRUG AND HERBAL REMEDY INTERACTIONS. There is an authoritative guide available for 89 USD called "InteractionsGuide: herb, nutrient, and drug interactions, Web applications" from MedicineWorks.com. View in LinkedIn

IF THE FUTURE IS "CUSTOMIZED WORK", it sounds uncannily like project-based work, or a synonym for outsourcing to consultants. If this prediction is even halfway true, the nature of the workforce within an organization will become more flexible and possibly more expendable. Combine that with the possibility that the office as we know it will be largely redundant, then the whole concept of work could be in for a big shakeup. http://www.jmorganmarketing.com/future-work-customized-work/ View in LinkedIn

SOME PREDICT THAT FUTURE UNIVERSITIES WILL BE DIFFERENT from today in response to economic and demographic forces. For instance, over 80% of professional degrees" "will be earned online, and competition for students will be worldwide. Also, the current university ranking system is likely to be replaced by a more transparent system. These dramatic changes will ultimately be more egalitarian and hopefully raise standards worldwide. http://lnkd.in/HQ3bJt? View in LinkedIn

CORPORATE VCs VS ONLINE CROWDFUNDING: a perspective. While many disagree with me, I continue to bet that Crowdfunding will dip its toe unto technology R&D companies such as Biopharma in the future. This is most akin to buying publicly traded stock in a company like Genentech. The consumer rarely understands the technical risks while making such an investment. http://bsr.london.edu/blog/post-124/index.html View in LinkedIn

BIO-BILLIONAIRES FUND COLLABORATIVE TRANSLATIONAL RESEARCH FACILITY IN GENEVA. This is one more investment in the future of Biopharma which is made by seasoned veterans, who are clearly optimistic about the industry's future. The clustering of expertise and international connections is invaluable for SME Biopharma companies. http://lnkd.in/BT5E97? View in LinkedIn

PRESS RELEASES IN ENGLISH are critical to gain visibility in the Biopharma community both on your website and through newswire services. However, as the world shrinks and more countries have significant Biopharma research companies, it is increasingly important to include press releases through Asian outlets in appropriate languages. This is an important step in slowly developing a credible world presence in the internet. Too many European technology companies fail to do either. http://lnkd.in/7PSK42 View in LinkedIn

BIG PHARMA'S SPENDING REFLECTS ITS TRUE MUSCLE, namely marketing and sales. These big organizations are powerful sales machines and cannot be rivaled by small companies, particularly in big physician access. In the case of specialty doc access, however, smaller specialty Pharma companies perform well, and in the case of generics, only very small sales forces are needed. http://lnkd.in/8CmrBM View in LinkedIn

INCREASED R&D SPENDING BY TOP TEN BIOTECH COMPANIES, may be good news, provided the lesson from Big Pharma is remembered. Big Research can result in big disappointments. Skunk works and SMEs have consistently punched above their weight in performance and been less prone to the Not Invented Here (NIH) syndrome that haunts large research undertakings. Undoubtedly subject matter for future B-School case studies, this is a clear trend. http://lnkd.in/jU3bAR View in LinkedIn

THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE again shows bold initiative to attract the top names to create a critical mass. This will become doubly significant as Japan's strategic initiative to prioritize pluripotent stem cell therapies kicks into action, and gives this traditionally underfunded and undervalued sector the horsepower that it needs. It will become the third leg of medicine's stool -- drugs, biologicals and now stem cells. http://lnkd.in/BDqXNE View in LinkedIn